Sign in

    Joshua Joseph

    Senior Equity Research Analyst at Noble Capital Markets

    Joshua Joseph is a Senior Equity Research Analyst at Noble Capital Markets, specializing in small- and mid-cap growth companies within the healthcare and biotechnology sectors. He covers a range of companies including BioVie Inc., INVO Bioscience, Alimera Sciences, and Jaguar Health, delivering actionable investment insights and maintaining a strong track record of timely, well-regarded recommendations, with performance metrics published on financial platforms such as TipRanks. Joseph began his career as a sell-side analyst in the mid-2010s, with previous experience at boutique investment firms before joining Noble Capital Markets in 2020. He holds Series 7, 63, 86, and 87 securities licenses and is registered with FINRA, bolstering his professional credibility as a trusted equity analyst.

    Joshua Joseph's questions to GEO GROUP (GEO) leadership

    Joshua Joseph's questions to GEO GROUP (GEO) leadership • Q4 2024

    Question

    Joshua Joseph inquired about the traction in discussions to activate idle facilities, the progress on asset sales like the Lawton facility, the quarterly spending cadence of the ICE investment, and the reason for the net operating income increase in the managed-only segment.

    Answer

    Executive Chairman George Zoley expressed confidence that all idle facilities would be contracted and activated in 2025. He confirmed the Lawton, Oklahoma facility is in a public sale process, with an appraisal expected next month. CFO Mark Suchinski affirmed the analyst's spending calculation. Zoley explained the managed-only margin pressure was due to proactive wage increases made to ensure facility security, with reimbursement requests currently pending with state clients.

    Ask Fintool Equity Research AI